Home


COVID-19: CARB-X remains open for business – virtually

CARB-X staff members are working from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.

Even as we cope with the COVID-19 pandemic, it is critical that we continue to support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.

 


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $222.06 million in 61 projects around the world.

222.06

$million

Invested

61

innovative

Projects

7

different

Countries

15

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

T2 Biosystems’ diagnostic panel can identify superbug drug resistance days faster than current methods

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

05.28.20

Boston, MA

Live Webinar – CARB-X - How to Prepare for an FDA Pre-IND Meeting: Planning for Success

05.29.20

 

Live Webinar: o2h ventures 6th ChaiTime Webinar Registration

06.09.20

Boston, MA

Live Webinar: GARDP/REVIVE – Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations

CARB-X News

  • 05.18.2020  |  CARB-X funds Facile Therapeutics to develop a new treatment to prevent recurring C. difficile bacterial infections full release

  • 05.11.2020  |  CARB-X funds 60th project – $220M invested so far, plus millions more if milestones are met full release

  • 05.11.2020  |  CARB-X awards Day Zero Diagnostics $6.2M to develop a new test that would diagnose deadly superbug infections faster and determine what antibiotic would be most effective full release

See All News

In The News

  • 05.05.2020  |  Antibiotic pipeline in peril from coronavirus and incentives system full story

  • 05.05.2020  |  Coronavirus lessons for the fight against ‘superbugs’ full story

  • 04.29.2020  |  Is AMR the next, but hidden, crisis? full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.